Quarterly ResultAug 5, 2026, 04:24 PM
Solventum Q2 Sales +2.2%, Adj. EPS +50.9%; Raises FY26 Guidance; Plans HIS Separation
AI Summary
Solventum reported strong second-quarter 2026 financial results, with reported sales increasing 2.2% to $2.2 billion and organic sales up 9.5%. Adjusted diluted earnings per share surged 50.9% to $2.55, and free cash flow reached $144 million. The company also announced its intent to separate its Health Information Systems business segment to enhance focus and shareholder value. Consequently, Solventum raised its full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow.
Key Highlights
- Q2 2026 reported sales increased 2.2% to $2.2 billion.
- Q2 2026 organic sales increased 9.5%.
- Q2 2026 adjusted diluted EPS rose 50.9% to $2.55.
- Q2 2026 free cash flow was $144 million, up 144.1%.
- Announced intent to separate its Health Information Systems business segment.
- Increased full-year 2026 organic sales growth guidance to +2.5% to +3.0%.
- Increased full-year 2026 adjusted EPS guidance to $7.10 to $7.20.
- Increased full-year 2026 free cash flow guidance to $200 million to $300 million.
Price Impact
More from SOLV